Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Nov 15, 2020; 12(11): 1237-1254
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1237
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1237
Figure 4 Overexpression of HOXD-AS2 inhibits gastric cancer cell proliferation and cell cycle progression and promotes apoptosis in vitro.
A and B: The effect of HOXD-AS2 on cell proliferation was determined by cell counting kit-8 assay. Cell proliferation was decreased after overexpression of HOXD-AS2 in SGC-7901 (P = 0.0019) and SNU-1 (P < 0.001) cells; C: Flow cytometry was used to detect the percentage of apoptotic cells in the pc-HOXD-AS2 and the control groups. The percentage of apoptotic cells was increased after overexpression of HOXD-AS2 in SGC-7901 (P = 0.007) and SNU-1 (P = 0.021) cells; D: The effect of HOXD-AS2 on cell cycle was measured by flow cytometry after 7-AAD staining in SGC-7901 and SNU-1 cells. aP < 0.05, bP < 0.01, eP < 0.001.
- Citation: Yao L, Ye PC, Tan W, Luo YJ, Xiang WP, Liu ZL, Fu ZM, Lu F, Tang LH, Xiao JW. Decreased expression of the long non-coding RNA HOXD-AS2 promotes gastric cancer progression by targeting HOXD8 and activating PI3K/Akt signaling pathway. World J Gastrointest Oncol 2020; 12(11): 1237-1254
- URL: https://www.wjgnet.com/1948-5204/full/v12/i11/1237.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i11.1237